RUMORED BUZZ ON ABBV-744 AS A POTENTIAL THERAPEUTIC OPTION FOR AGGRESSIVE CANCERS

In Phase C, contributors will obtain ABBV-744 and oral navitoclax. In Phase D, participants will get ABBV-744 and ruxolitinib. Contributors will receive treatment right up until condition progression or maybe the individuals are not able to tolerate the study drugs.- Participant consumed grapefruit or grapefruit products within three days prior to